These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19679884)

  • 1. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.
    Xue SA; Gao L; Thomas S; Hart DP; Xue JZ; Gillmore R; Voss RH; Morris E; Stauss HJ
    Haematologica; 2010 Jan; 95(1):126-34. PubMed ID: 19679884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells.
    Xue SA; Gao L; Hart D; Gillmore R; Qasim W; Thrasher A; Apperley J; Engels B; Uckert W; Morris E; Stauss H
    Blood; 2005 Nov; 106(9):3062-7. PubMed ID: 16020516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
    Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
    Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
    Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia.
    Ochi T; Fujiwara H; Yasukawa M
    J Biomed Biotechnol; 2010; 2010():521248. PubMed ID: 20454585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients.
    Gao L; Xue SA; Hasserjian R; Cotter F; Kaeda J; Goldman JM; Dazzi F; Stauss HJ
    Transplantation; 2003 May; 75(9):1429-36. PubMed ID: 12792492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
    Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
    Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.
    Fujiwara H; Ochi T; Ochi F; Miyazaki Y; Asai H; Narita M; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Leukemia; 2015 Dec; 29(12):2393-401. PubMed ID: 26104661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.
    Iwami K; Natsume A; Ohno M; Ikeda H; Mineno J; Nukaya I; Okamoto S; Fujiwara H; Yasukawa M; Shiku H; Wakabayashi T
    Neuro Oncol; 2013 Jun; 15(6):747-58. PubMed ID: 23460320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.
    Romano E; Cotari JW; Barreira da Silva R; Betts BC; Chung DJ; Avogadri F; Fink MJ; St Angelo ET; Mehrara B; Heller G; Münz C; Altan-Bonnet G; Young JW
    Blood; 2012 May; 119(22):5182-90. PubMed ID: 22510877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.
    Stauss HJ; Thomas S; Cesco-Gaspere M; Hart DP; Xue SA; Holler A; King J; Wright G; Perro M; Pospori C; Morris E
    Blood Cells Mol Dis; 2008; 40(1):113-6. PubMed ID: 17855129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
    Milone MC; Fish JD; Carpenito C; Carroll RG; Binder GK; Teachey D; Samanta M; Lakhal M; Gloss B; Danet-Desnoyers G; Campana D; Riley JL; Grupp SA; June CH
    Mol Ther; 2009 Aug; 17(8):1453-64. PubMed ID: 19384291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
    Asai H; Fujiwara H; An J; Ochi T; Miyazaki Y; Nagai K; Okamoto S; Mineno J; Kuzushima K; Shiku H; Inoue H; Yasukawa M
    PLoS One; 2013; 8(2):e56820. PubMed ID: 23441216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen-specific cellular immunotherapy of leukemia.
    Van Driessche A; Gao L; Stauss HJ; Ponsaerts P; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    Leukemia; 2005 Nov; 19(11):1863-71. PubMed ID: 16121214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.
    Lynn RC; Poussin M; Kalota A; Feng Y; Low PS; Dimitrov DS; Powell DJ
    Blood; 2015 May; 125(22):3466-76. PubMed ID: 25887778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
    Oka Y; Udaka K; Tsuboi A; Elisseeva OA; Ogawa H; Aozasa K; Kishimoto T; Sugiyama H
    J Immunol; 2000 Feb; 164(4):1873-80. PubMed ID: 10657636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
    Jaigirdar A; Rosenberg SA; Parkhurst M
    J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.
    Katsuhara A; Fujiki F; Aoyama N; Tanii S; Morimoto S; Oka Y; Tsuboi A; Nakajima H; Kondo K; Tatsumi N; Nakata J; Nakae Y; Takashima S; Nishida S; Hosen N; Sogo S; Oji Y; Sugiyama H
    Anticancer Res; 2015 Mar; 35(3):1251-61. PubMed ID: 25750272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice.
    Najima Y; Tomizawa-Murasawa M; Saito Y; Watanabe T; Ono R; Ochi T; Suzuki N; Fujiwara H; Ohara O; Shultz LD; Yasukawa M; Ishikawa F
    Blood; 2016 Feb; 127(6):722-34. PubMed ID: 26702062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.